¼¼°èÀÇ ÀÇ·á µ¥Æä·Ï»ç¹Î¸Þ½Ç·¹ÀÌÆ® ½ÃÀå º¸°í¼­(2025³â)
Medical Deferoxamine Mesylate Global Market Report 2025
»óǰÄÚµå : 1760608
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÇ·á µ¥Æä·Ï»ç¹Î¸Þ½Ç·¹ÀÌÆ® ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. öºÐ °úºÎÇÏ ÁúȯÀÇ À¯º´·ü Áõ°¡, Èñ±ÍÁúȯ¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿øÃ¥, Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ¿¬±¸ °³¹ß¿¡ ´ëÇÑ ÅõÀÚ È®´ë µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£¿¡ À־ÀÇ ÁÖ¿äÇÑ µ¿ÇâÀ¸·Î¼­´Â »õ·Î¿î µå·¯±× µô¸®¹ö¸® ½Ã½ºÅÛÀÇ Áøº¸, À¯ÀüÀÚ Ä¡·á¿ÍÀÇ ÅëÇÕ, Àå½Ã°£ ÀÛ¿ëÇü Á¦Á¦ÀÇ °³¹ß, ų·¹ÀÌÆ® ¿ä¹ýÀÇ ÁøÀü µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

öºÐ °úÀ×ÁõÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ÀÇ·á µ¥Æä·Ï»ç¹Î¸Þ½Ç·¹ÀÌÆ® ½ÃÀåÀÇ È®´ë¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö´Â ü³» öºÐÀÇ °úµµÇÑ ÃàÀûÀ¸·Î Ư¡Áö¾îÁö¸ç, À¯ÀüÀû ¿äÀÎ, ºó¹øÇÑ ¼öÇ÷ ¶Ç´Â ƯÁ¤ ¸¸¼º ÁúȯÀ¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ³ª¾Æ°¡, À§ÇèÀÌ ÀÖ´Â Àα¸ Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ öºÐ °úÀ×ÁõÀÇ ¹ß»ý·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Electronic Journal of General Medicine ÀâÁöÀÇ 2023³â 3¿ù º¸°í¿¡ µû¸£¸é ȯÀÚÀÇ 10.73%(1,085¸í)°¡ ¥á-»ì¶ó¼¼¹Ì¾Æ, 2.24%(227¸í)°¡ ¥â-»ì¶ó¼¼¹Ì¾Æ, 0 .29%(29¸í)°¡ µÎ °¡Áö µ¹¿¬º¯À̸¦ °¡Áö°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ÀÇ·á µ¥Æä·Ï»ç¹Î¸Þ½Ç·¹ÀÌÆ® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ȯÀÚ Á¢±Ù °³¼±, Ä¡·á ºñ¿ë Àý°¨, ¼¼°è ½ÃÀå °æÀï·Â °­È­¸¦ À§ÇØ Á¦³×¸¯ ÀǾàǰ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ij³ª´Ù Á¦¾àȸ»ç ÆÛ¸Ó»çÀ̾𽺻ç´Â 2023³â 1¿ù, ÀÚµ¥´©ÀÇ ºñ¿ë È¿À²ÀûÀÎ ´ëü¾à PRpms-DEFERASIROX(TYPE) J)¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¾àÀº ¼Ò¾Æ ¹× ¼ºÀÎ ºóÇ÷ ¶Ç´Â »ç¶ó ¼¼¹Ì¾Æ ȯÀÚ¿¡¼­ ¸¸¼º öºÐ °ú´ÙÁõÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ¸ç 90mg°ú 360mgÀÇ Á¤Á¦¿¡¼­ µ¿ÀÏÇÑ ¾ÈÀü¼º°ú È¿´ÉÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Medical deferoxamine mesylate is a medication used to remove excess iron from the body. It is primarily prescribed to individuals with dangerously high iron levels, often due to frequent blood transfusions. The drug binds to the excess iron, enabling the body to safely eliminate it through urine or bile.

The main types of medical deferoxamine mesylate products include injectable, oral, and topical formulations. Injectable products are delivered into the body using a needle and syringe, with administration methods including subcutaneous, intramuscular, and intravenous routes. These products are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Key applications of deferoxamine mesylate include the treatment of iron overload disorders, aluminum toxicity, and acute iron poisoning. It is primarily used by hospitals and clinics among other healthcare providers.

The medical deferoxamine mesylate market research report is one of a series of new reports from The Business Research Company that provides medical deferoxamine mesylate market statistics, including the medical deferoxamine mesylate industry global market size, regional shares, competitors with the medical deferoxamine mesylate market share, detailed medical deferoxamine mesylate market segments, market trends, and opportunities, and any further data you may need to thrive in the medical deferoxamine mesylate industry. This medical deferoxamine mesylate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The medical deferoxamine mesylate market size has grown strongly in recent years. It will grow from $1.18 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth observed in the historical period can be linked to the increasing prevalence of iron overload disorders, a rise in cases of thalassemia and sickle cell anemia, higher global blood transfusion rates, expansion of healthcare infrastructure, greater government funding for rare disease treatments, and improved diagnosis rates for chronic iron-related conditions.

The medical deferoxamine mesylate market size is expected to see strong growth in the next few years. It will grow to $1.80 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The expected growth in the forecast period is driven by factors such as the rising prevalence of thalassemia and sickle cell disease, growing demand for iron chelation therapies, broader access to healthcare, increasing awareness of iron overload complications, supportive government initiatives for rare diseases, and more investments in research and development by pharmaceutical companies. Key trends in the forecast period include advancements in new drug delivery systems, integration with gene therapy treatments, the development of long-acting formulations, and progress in chelation therapy.

The growing prevalence of iron overload disorders is anticipated to drive the expansion of the medical deferoxamine mesylate market in the coming years. These disorders, characterized by an excessive accumulation of iron in the body, can result from genetic factors, frequent blood transfusions, or certain chronic illnesses. The increased use of long-term blood transfusions for managing chronic hemoglobinopathies, alongside improved patient survival rates, has contributed to a larger population at risk, thereby increasing the incidence of iron overload disorders. Medical deferoxamine mesylate plays a crucial role in treating these conditions by removing excess iron, preventing organ damage, and assisting patients with conditions such as thalassemia and hemochromatosis. For example, a March 2023 report from the Electronic Journal of General Medicine noted that 10.73% of patients (1,085) had alpha-thalassemia, 2.24% (227) had beta-thalassemia, and 0.29% (29) had both mutations. Thus, the rising prevalence of iron overload disorders is driving the growth of the medical deferoxamine mesylate market.

Key players in the medical deferoxamine mesylate market are focusing on developing generic versions of drugs to improve patient access, lower treatment costs, and enhance their competitive standing in the global market. Generic drugs, which are more affordable alternatives to branded medicines, contain the same active ingredients and provide the same therapeutic benefits once the original patent expires. For example, in January 2023, Pharmascience Inc., a Canadian pharmaceutical company, introduced PRpms-DEFERASIROX (TYPE J), a cost-effective substitute for Jadenu. This medication, used to treat chronic iron overload in both children and adults with anemia or thalassemia, offers the same safety and efficacy in 90 mg and 360 mg tablet forms.

In September 2024, Mitem Pharma, a French pharmaceutical company, acquired the global rights to DESFERAL (deferoxamine mesylate) from Novartis AG for an undisclosed amount. This acquisition strengthens Mitem Pharma's position in the iron chelation therapy market and enhances its portfolio with a well-established treatment for managing iron overload disorders. Novartis AG, a Swiss-based pharmaceutical company, is known for producing therapeutic drugs for rare diseases.

Major players in the medical deferoxamine mesylate market are McKesson Corporation, Novartis AG, Merck KGaA, Teva Pharmaceutical Industries Inc. (TAPI), Intas Pharmaceuticals Ltd., Fresenius Kabi AG, Apotex Inc., Fareva SA, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Hospira Inc., Cayman Chemical Company, Inc., Selleck Chemicals LLC, Tocris Bioscience, Bills Biotech, JIGS CHEMICAL LIMITED., Manus Aktteva Biopharma LLP, Merit Pharmaceuticals Inc.

North America was the largest region in the medical deferoxamine mesylate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medical deferoxamine mesylate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the medical deferoxamine mesylate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical deferoxamine mesylate market consists of sales of infusion pumps, syringes, and generic version of drug. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medical Deferoxamine Mesylate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on medical deferoxamine mesylate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for medical deferoxamine mesylate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medical deferoxamine mesylate market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Medical Deferoxamine Mesylate Market Characteristics

3. Medical Deferoxamine Mesylate Market Trends And Strategies

4. Medical Deferoxamine Mesylate Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Medical Deferoxamine Mesylate Growth Analysis And Strategic Analysis Framework

6. Medical Deferoxamine Mesylate Market Segmentation

7. Medical Deferoxamine Mesylate Market Regional And Country Analysis

8. Asia-Pacific Medical Deferoxamine Mesylate Market

9. China Medical Deferoxamine Mesylate Market

10. India Medical Deferoxamine Mesylate Market

11. Japan Medical Deferoxamine Mesylate Market

12. Australia Medical Deferoxamine Mesylate Market

13. Indonesia Medical Deferoxamine Mesylate Market

14. South Korea Medical Deferoxamine Mesylate Market

15. Western Europe Medical Deferoxamine Mesylate Market

16. UK Medical Deferoxamine Mesylate Market

17. Germany Medical Deferoxamine Mesylate Market

18. France Medical Deferoxamine Mesylate Market

19. Italy Medical Deferoxamine Mesylate Market

20. Spain Medical Deferoxamine Mesylate Market

21. Eastern Europe Medical Deferoxamine Mesylate Market

22. Russia Medical Deferoxamine Mesylate Market

23. North America Medical Deferoxamine Mesylate Market

24. USA Medical Deferoxamine Mesylate Market

25. Canada Medical Deferoxamine Mesylate Market

26. South America Medical Deferoxamine Mesylate Market

27. Brazil Medical Deferoxamine Mesylate Market

28. Middle East Medical Deferoxamine Mesylate Market

29. Africa Medical Deferoxamine Mesylate Market

30. Medical Deferoxamine Mesylate Market Competitive Landscape And Company Profiles

31. Medical Deferoxamine Mesylate Market Other Major And Innovative Companies

32. Global Medical Deferoxamine Mesylate Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Medical Deferoxamine Mesylate Market

34. Recent Developments In The Medical Deferoxamine Mesylate Market

35. Medical Deferoxamine Mesylate Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â